CA2201327A1 - Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance - Google Patents

Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance

Info

Publication number
CA2201327A1
CA2201327A1 CA002201327A CA2201327A CA2201327A1 CA 2201327 A1 CA2201327 A1 CA 2201327A1 CA 002201327 A CA002201327 A CA 002201327A CA 2201327 A CA2201327 A CA 2201327A CA 2201327 A1 CA2201327 A1 CA 2201327A1
Authority
CA
Canada
Prior art keywords
leu
seq
tumor rejection
glu
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002201327A
Other languages
English (en)
Inventor
Pierre Van Der Bruggen
Thierry Boon-Falleur
Benoit Van Den Eynde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2201327A1 publication Critical patent/CA2201327A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001178—Tumor rejection antigen precursor [TRAP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des compositions présentant de meilleurs effets immunogènes. Ces compositions contiennent au moins un peptide qui, lorsqu'il est complexé à une molécule d'une surface cellulaire, telle qu'un MCH (complexe majeur d'histocompatibilité), HLA (système majeur d'histocompatibilité) ou un récepteur des lymphocytes B, provoque une réponse immune. Les compositions renferment des adjuvants tels que les saponines qui potentialisent la réponse immune. Les compositions notamment préférées sont celles qui stimulent les réponses cytolytiques des lymphocytes T, tels que les peptides qui satisfont aux critères de liaison du CMH, et tels que les peptides dérivés des précurseurs d'antigènes de rejet de tumeurs, y compris les peptides dérivés de MAGE, BAGE et GAGE.
CA002201327A 1994-09-30 1995-09-27 Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance Abandoned CA2201327A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31596194A 1994-09-30 1994-09-30
US08/315,961 1994-09-30

Publications (1)

Publication Number Publication Date
CA2201327A1 true CA2201327A1 (fr) 1996-04-11

Family

ID=23226857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002201327A Abandoned CA2201327A1 (fr) 1994-09-30 1995-09-27 Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance

Country Status (7)

Country Link
EP (1) EP0782453A1 (fr)
JP (1) JPH10511639A (fr)
CN (1) CN1159759A (fr)
AU (1) AU690371B2 (fr)
CA (1) CA2201327A1 (fr)
WO (1) WO1996010413A1 (fr)
ZA (1) ZA958229B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US20060029653A1 (en) 1997-01-29 2006-02-09 Cronk Peter J Therapeutic delivery system
WO1999004265A2 (fr) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Acides nucleiques et polypeptides associes au cancer
DK1659179T3 (da) 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
MX2009002195A (es) 2006-08-30 2009-05-28 David William Smith Metodo para impartir una rigidez mono-axial o multi-axial a materiales extruidos y productos que resultan de los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof

Also Published As

Publication number Publication date
WO1996010413A1 (fr) 1996-04-11
ZA958229B (en) 1996-04-24
AU690371B2 (en) 1998-04-23
AU3886495A (en) 1996-04-26
CN1159759A (zh) 1997-09-17
EP0782453A1 (fr) 1997-07-09
JPH10511639A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
AU723147B2 (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
EP0752876B1 (fr) Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1
AU668772B2 (en) Isolated nonapeptide derived from mage-3 gene and presented by HLA-A1, and uses thereof
AU693664B2 (en) Isolated nonapeptides presented by HLA molecules, and uses thereof
US5462871A (en) Isolated nucleic acid molecules which encode MAGE derived nonapeptides
US5405940A (en) Isolated nonapeptides derived from MAGE genes and uses thereof
TWI285648B (en) Compositions and methods for WT1 specific immunotherapy
DE69727966T2 (de) Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen
AU682956B2 (en) Isolated, mage-3 derived peptides which complex with HLA-A2 molecules and uses thereof
CA2201327A1 (fr) Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance
JP2002512202A (ja) メラノーマの免疫治療用のワクチンアジュバント

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued